PharmaFocus Today – Page 41 – media

Tumor drugs without OS are also hanging in China

Before this, furiquintinib was regarded as another effective treatment option for gastric cancer patients. After all, gastric cancer is the fifth most common cancer in the world, and my country is a country with a high incidence of gastric cancer, with a large number of patients. With the continuous development of precision medicine, PD-1 combined with chemotherapy has become a new standard for first-line treatment of advanced gastric cancer. However, both in China and around the world, there is still a lack of treatment options available for second-line and above patients. Global pharmaceutical companies have deployed a large number of research in this field to promote clinical trials including PD-1, ADC, and VEGFR inhibitors. Among them, VEGFR inhibitors play a vital role in inhibiting tumor angiogenesis, and studies have shown that gastric cancer tissues often express high levels of VEGF, which is associated with more advanced disease and poor prognosis. ...
- Source: drugdu
- 86
- September 3, 2024
Focusing on complement, standardized diagnosis and treatment of rare diseases usher in a new chapter

So far, the 2024 medical insurance catalog adjustment has announced the drugs and related information that have passed the formal review. From the draft for comments, rare disease drugs are still one of the focuses of the medical insurance catalog adjustment. Rare diseases are also called “orphan diseases”. Most of them are congenital diseases, chronic diseases, and may be life-threatening. Although the incidence of rare diseases is low, there are many types of diseases and the number of patients cannot be underestimated. At present, there are more than 7,000 confirmed rare diseases in the world, and there are about 20 million rare disease patients in China1. For a long time, the clinical phenotypes of rare diseases and common diseases overlap greatly, and early diagnosis is difficult, so the misdiagnosis and missed diagnosis rates are high. According to statistics from the National Organization for Rare Diseases in the United States, among ...
- Source: drugdu
- 54
- September 3, 2024
stable and improving performance in ringgit, the benefits of overseas market development gradually appeared

On August 28, Buchang Pharma (603858) released its 2024 semi-annual report. During the report period, the company realized operating income of 5.432 billion yuan; realized attributable net profit of 231 million yuan; net cash flow from operating activities was 497 million yuan, an increase of 85.62%, the company’s cash reserves are more adequate. In the context of general industry pressure, Buchang Pharma still shows the strong operating resilience of leading enterprises. During the reporting period, the company actively carried out research and development of multiple types of drugs and gradually perfected the big health industry. Since its establishment, Buchang Pharma has become an important force in promoting local economic development. As of July 2024, Buchang Pharma has accumulated more than 30 billion yuan in national tax payments, making significant contributions to the sustainable and sound development of the local economy. According to statistics, since the listing of eight years, Buchang ...
- Source: drugdu
- 56
- September 3, 2024
Tiktok is so convenient for selling medicines and medical devices

Tiktok is so convenient for selling medicines and medical devices! Tiktok, as the world’s leading short video platform, has a huge user base covering all age groups and interest areas. This provides a huge potential market for pharmaceutical companies, which can directly reach a large number of target consumers. The platform supports direct links to e-commerce platforms or corporate official websites to facilitate users to purchase. Pharmaceutical and medical device companies can embed purchase links in videos or guide users to follow stores to promote sales conversion. At the same time, through Tiktok’s live broadcast function, companies can also display products, answer user questions, etc., to further promote sales. It’s so convenient! How to do Tiktok well? Pharmaceutical and medical device companies need to make efforts in many aspects such as clear goals, precise positioning, high-quality content, effective conversion and compliant operations to do marketing on Tiktok. Only through continuous optimization ...
- Source: drugdu
- 68
- September 2, 2024
Medtronic platform acquired

Recently, PaceMate, a provider of cardiac remote monitoring solutions, announced that it has successfully acquired Medtronic’s localized cardiac workflow solution Paceart Optima. However, the financial details of the transaction have not yet been disclosed to the public. As an innovator of cardiac health data management solutions, PaceMate has gained wide recognition in recent years for its remote monitoring technology. The integration of the Paceart Optima system is expected to add nearly 1,000 new clinic partners worldwide. For Medtronic, this divestiture is in line with its overall strategy of focusing resources on core innovation and therapeutic advances. PaceMate has further consolidated its market leadership and expanded its global influence by increasing the depth and breadth of its services. Next, Medtronic’s cardiac rhythm management (CRM) business will work closely with PaceMate to ensure a smooth transition. https://mp.weixin.qq.com/s/GQmozVWWkMxQcAebSM4T-Q
- Source: drugdu
- 95
- September 2, 2024
The Nation’s First Stem Cell Drug Production License Issued Cell Therapy Track to Meet the Development Opportunities

Beijing Drug Administration held a half-year working meeting, at which the work of issuing the country’s first stem cell “drug production license” was particularly recognized. According to the search results of “Administrative License Information” on the website of Beijing Drug Administration, Platinum Bio-Excellence Biotechnology (Beijing) Co., Ltd. is the first company to obtain the national stem cell drug production license. The issuance of the Drug Manufacturing License is of epoch-making significance as it is the first drug manufacturing license specifically for stem cell drugs in China. The issuance of the Drug Manufacturing License signifies that the relevant enterprise has obtained the legal qualification and ability to manufacture stem cell drugs. In recent years, with the introduction of policies such as the “14th Five-Year Plan” for the development of bio-economy, China has clearly put forward the development of new technologies such as stem cell therapy, strengthening the synergy between industry, academia, ...
- Source: drugdu
- 69
- September 2, 2024
HEC Pharmaceuticals and Shamshi Technology held a joint laboratory unveiling ceremony

On August 28, 2024, HEC Pharmaceuticals and Deepin Technology held a joint laboratory unveiling ceremony. The joint laboratory of HEC Pharmaceuticals and Deepin Technology focuses on high-value R&D scenarios and technical R&D bottlenecks in the field of biopharmaceuticals, promoting science and technology from The complete closed loop from source innovation to industrial implementation forms a complete closed loop, jointly exploring the industrial transformation and verification of cutting-edge AI technologies. The unveiling ceremony announced the cooperation relationship between the two parties and promoted close cooperation between the two parties in future multi-level projects. Co., Ltd. (hereinafter referred to as East Sunshine Pharmaceutical), as the domestic anti-influenza “top” brand, its anti-influenza drug Kewei® is the top brand of oseltamivir phosphate, and in February this year, it was awarded the The company has obtained three certifications: “the largest oseltamivir production base in the world”, “the largest oseltamivir production in the world in the ...
- Source: drugdu
- 72
- September 1, 2024
First domestic generic! Jimin Kexin’s Ropinirole Hydrochloride Sustained-Release Tablets approved for marketing

Nanjing Hengsheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Nanjing Hengsheng”), a subsidiary of Jimin Trustworthy Group, received the “Drug Registration Certificate” approved and issued by the National Medical Products Administration (NMPA), approving the company’s ropinirole hydrochloride sustained-release tablets (specification: 2mg) for sale. This variety is the first generic drug of ropinirole hydrochloride sustained-release tablets approved for sale in China. It is mainly used to treat patients with Parkinson’s disease in the early, middle and late stages and non-motor symptoms. It is developed by the Innovative Technology Drug Research Institute under Jimin Trustworthy Group and Nanjing Hengsheng is in production. Parkinson’s disease is a common degenerative disease of the elderly nervous system. Symptoms include resting tremor, muscle rigidity, bradykinesia, cognitive impairment, etc. The condition worsens over time, causing great burdens on patients’ families and society. Ropinirole hydrochloride is a new dopamine receptor agonist that can enter the central nervous system ...
- Source: drugdu
- 55
- September 1, 2024
Vice President Wang Maochun paid a working visit to the China Center for Assistive Devices for Persons with Disabilities

On the morning of August 9, Vice President Wang Maochun and his delegation paid a working visit to the China Center for Assistive Devices for Persons with Disabilities, and had pragmatic exchanges with Kong Deming, Secretary of the Party Branch and Director of the Center, on the development of the assistive device industry and the participation of Chinese assistive device companies in international cooperation. The Chamber of Commerce’s External Cooperation Department and Exhibition Department accompanied the meeting. Vice President Maochun briefly introduced the basic situation of the Medical Insurance Chamber of Commerce in helping domestic pharmaceutical companies to develop internationally over the years, and highly appreciated the contributions of the Assistive Devices Center in promoting the distribution of assistive device products and improving the level of technological research and development innovation. He said that the Medical Insurance Chamber of Commerce is willing to work with the Assistive Devices Center to ...
- Source: drugdu
- 74
- September 1, 2024
Tonghua Jinma Oral Drug Succinium Octahydroaminoacridine Tablets Listing Application Accepted

On the evening of August 29, Tonghua Jinma announced that the company recently received the State Drug Administration issued a listing application for succinium octahydroaminoacridine tablets “Notice of Acceptance”, the oral drug for light, moderate Alzheimer’s disease (Alzheimer’s disease, AD) treatment. On the same day, Tonghua Jinma plate rushed to a halt, closing up 9.98%, closing price of 14.54 yuan / share. Alzheimer’s disease as one of the most common neurodegenerative diseases, the number of its patients with the aging trend of the population and rising. According to the introduction, Succinum Octahydroaminoacridine Tablets is a new, potent, clear mechanism of action of cholinesterase inhibitors, is a new chemical 1 class of drugs with complete independent intellectual property rights, new chemical molecular structure, domestic and foreign have not been marketed. The results of the main pharmacodynamic study show that the drug exhibits strong inhibition of both acetylcholinesterase and butyrylcholinesterase, and by ...
- Source: drugdu
- 66
- September 1, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.